TrialsgrambetaRCTs are beautiful

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

This guideline cites 9 of the 58 landmark trials in our Nephrology register.

The KDIGO 2024 guideline is the first full revision of the CKD framework since 2012. It keeps the CGA (cause–GFR–albuminuria) staging, adds cystatin C to eGFR confirmation, endorses the KFRE risk equations for referral and planning, and — the substantive change — builds a layered kidney-protective regimen around RAS blockade, SGLT2 inhibition, nonsteroidal MRA and statins. Since March 2026 a focused update of Chapter 3 (delaying progression and managing CKD complications) has been under way, re-examining SGLT2 inhibitors, nonsteroidal MRAs and GLP-1 receptor agonists specifically in CKD without type-2 diabetes; diabetic CKD is being handled separately by the Diabetes work group. Until that update lands, the 2024 text remains the standard. The register's landmark trials behind these recommendations are grouped by theme below.

RAS blockade & proteinuria1

  • 2001IDNT Core⁠Nephrology · CKD · RAAS blockadeIn 1,715 patients with type 2 diabetes and nephropathy, irbesartan reduced progression of the renal composite compared with amlodipine or placebo.Read →

SGLT2 inhibition3

  • 2023EMPA-KIDNEY⁠Nephrology · CKD · SGLT2 inhibitorsIn 6,609 patients across a broad spectrum of CKD, empagliflozin reduced kidney-disease progression or cardiovascular death compared with placebo.HR 0.7295% CI 0.64-0.82Read →
  • 2020DAPA-CKD Core⁠Nephrology · CKD · SGLT2 inhibitorsIn 4,304 patients with CKD with or without diabetes, dapagliflozin reduced the composite of ≥50% eGFR decline, ESKD or renal/CV death compared with placebo.HR 0.6195% CI 0.51-0.72Read →
  • 2019CREDENCE Core⁠Nephrology · CKD · SGLT2 inhibitorsIn 4,401 patients with type 2 diabetes and albuminuric CKD on maximal RAS blockade, canagliflozin reduced the composite of ESKD, creatinine doubling or renal/CV death compared with placebo.HR 0.7095% CI 0.59-0.82Read →

Nonsteroidal mineralocorticoid-receptor antagonism2

  • 2021FIGARO-DKD⁠Nephrology · CKD · Nonsteroidal MRAIn 7,437 patients with type 2 diabetes and CKD, finerenone reduced the cardiovascular composite compared with placebo.HR 0.8795% CI 0.76-0.98Read →
  • 2020FIDELIO-DKD Core⁠Nephrology · CKD · Nonsteroidal MRAIn 5,734 patients with type 2 diabetes and CKD, finerenone reduced the composite of kidney failure, ≥40% eGFR decline or renal death compared with placebo.HR 0.8295% CI 0.73-0.93Read →

Blood-pressure targets1

  • 2017SPRINT-CKD⁠Nephrology · CKD · Blood-pressure targetsIn 2,646 participants with chronic kidney disease, an intensive systolic-BP target below 120 mmHg reduced all-cause mortality compared with a target below 140 mmHg.HR 0.72CI 0.53-0.99Read →

Endothelin-receptor antagonism1

  • 2019SONAR⁠Nephrology · CKD · Endothelin antagonistsIn 2,648 patients with type 2 diabetes and CKD selected for response, atrasentan reduced the composite of creatinine doubling or ESKD compared with placebo.HR 0.6595% CI 0.49-0.88Read →

Hyperkalaemia: keeping RAS inhibitors on board1

  • 2015OPAL-HK⁠Nephrology · Dialysis · HyperkalaemiaIn 243 patients with CKD and hyperkalaemia on RAAS inhibitors, patiromer lowered serum potassium and recurrent hyperkalaemia compared with placebo withdrawal.15% vs 60%Read →

Published since the guideline1

  • 2024FLOW Core⁠Nephrology · CKD · GLP-1 RAIn 3,533 patients with type 2 diabetes and CKD, semaglutide reduced the composite of kidney failure, ≥50% eGFR decline or renal/CV death compared with placebo.HR 0.7695% CI 0.66-0.88Read →

Cited landmark trials not yet in the register6

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 2011SHARP

    Simvastatin plus ezetimibe reduced atherosclerotic events across the CKD spectrum, including dialysis.

  • 2008ONTARGET

    Combined ACE inhibitor plus ARB worsened renal outcomes — the basis for advising against dual RAS blockade.

  • 2012ALTITUDE

    Aliskiren added to RAS blockade in type-2 diabetes: harm, stopped early.

  • 2022STOP-ACEi

    Discontinuing RAS inhibitors in advanced CKD did not improve eGFR — supports continuing therapy.

  • 2020CKD-FIX

    Allopurinol did not slow eGFR decline — against urate-lowering for kidney protection.

  • 1994MDRD

    Protein restriction and blood-pressure targets in CKD; the source of the classic MDRD eGFR equation.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.